Anjali Prashar
Research Subjects
Anjali Prashar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Amit Kumar Singh
1 shared publication- Antje Labes
Flensburg University of Applied Sciences, ZAiT
1 shared publication - Bernhard Ellinger
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, ScreeningPort, 22525 Hamburg, Germany
1 shared publication - Bethlehem Kebede
Hypha Discovery Ltd., Russell Building, Brunel Science Park, Kingston Lane, Uxbridge, Middlesex UB8 3PQ, UK
1 shared publication Faraha Siddiqui
1 shared publication- Janina Rahlff
Aero-Aquatic Virus Research Group, Faculty of Mathematics and Computer Science, Friedrich Schiller University Jena, Jena, Germany
1 shared publication
Latest Publications
- Open Access
- 23 March 2017
- Published by MDPI AG in Marine Drugs
- Vol. 15 (4) , 84
Establishing the Secondary Metabolite Profile of the Marine Fungus: Tolypocladium geodes sp. MF458 and Subsequent Optimisation of Bioactive Secondary Metabolite Production
As part of an international research project, the marine fungal strain collection of the Helmholtz Centre for Ocean Research (GEOMAR) research centre was analysed for secondary metabolite profiles associated with anticancer activity. Strain MF458 was identified as Tolypocladium geodes, by internal transcribed spacer region (ITS) sequence similarity and its natural product production profile. By using five different media in two conditions and two time points, we were able to identify eight natural products produced by MF458. As well as cyclosporin A (1), efrapeptin D (2), pyridoxatin (3), terricolin A (4), malettinins B and E (5 and 6), and tolypocladenols A1/A2 (8), we identified a new secondary metabolite which we termed tolypocladenol C (7). All compounds were analysed for their anticancer potential using a selection of the NCI60 cancer cell line panel, with malettinins B and E (5 and 6) being the most promising candidates. In order to obtain sufficient quantities of these compounds to start preclinical development, their production was transferred from a static flask culture to a stirred tank reactor, and fermentation medium development resulted in a nearly eight-fold increase in compound production. The strain MF458 is therefore a producer of a number of interesting and new secondary metabolites and their production levels can be readily improved to achieve higher yields.
- 23 March 2017
- Published by MDPI AG in Marine Drugs
- Vol. 15 (4) , 84
Open AccessEstablishing the Secondary Metabolite Profile of the Marine Fungus: Tolypocladium geodes sp. MF458 and Subsequent Optimisation of Bioactive Secondary Metabolite Production
As part of an international research project, the marine fungal strain collection of the Helmholtz Centre for Ocean Research (GEOMAR) research centre was analysed for secondary metabolite profiles associated with anticancer activity. Strain MF458 was identified as Tolypocladium geodes, by internal transcribed spacer region (ITS) sequence similarity and its natural product production profile. By using five different media in two conditions and two time points, we were able to identify eight natural products produced by MF458. As well as cyclosporin A (1), efrapeptin D (2), pyridoxatin (3), terricolin A (4), malettinins B and E (5 and 6), and tolypocladenols A1/A2 (8), we identified a new secondary metabolite which we termed tolypocladenol C (7). All compounds were analysed for their anticancer potential using a selection of the NCI60 cancer cell line panel, with malettinins B and E (5 and 6) being the most promising candidates. In order to obtain sufficient quantities of these compounds to start preclinical development, their production was transferred from a static flask culture to a stirred tank reactor, and fermentation medium development resulted in a nearly eight-fold increase in compound production. The strain MF458 is therefore a producer of a number of interesting and new secondary metabolites and their production levels can be readily improved to achieve higher yields.
- 1 March 2012
- Published by Elsevier in Fitoterapia
- Vol. 83 (2) , 255-265
Synthetic and green vegetable isothiocyanates target red blood leukemia cancers
- 1 March 2012
- Published by Elsevier in Fitoterapia
- Vol. 83 (2) , 255-265
Synthetic and green vegetable isothiocyanates target red blood leukemia cancers